Details

Autor(en) / Beteiligte

• Zhang, Jing
• Liu, Lang‐Li
• Gong, Jing‐Yu
• Hao, Chen‐Zhi
• Qiu, Yi‐Ling
• Lu, Yi
• Feng, Jia‐Yan
• Li, Jia‐Qi
• Li, Zhong‐Die
• Wang, Meng‐Xuan
• Xing, Qing‐He
• Knisely, A. S.
• Wang, Jian‐She

Titel

TJP2 hepatobiliary disorders: Novel variants and clinical diversity

Ist Teil von

• Human mutation, 2020-02, Vol.41 (2), p.502-511

Ort / Verlag

United States: Hindawi Limited

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• To assess the spectrum of pediatric clinical phenotypes in TJP2 disease, we reviewed records of our seven patients in whom intrahepatic cholestasis was associated with biallelic TJP2 variants (13; 12 novel) and correlated clinical manifestations with mutation type. The effect of a splicing variant was analyzed with a minigene assay. The effects of three missense variants were analyzed with protein expression in vitro. Our patients had both remitting and persistent cholestasis. Three exhibited growth retardation. Six responded to treatment with cholestyramine, ursodeoxycholic acid, or both. Two had cholecystolithiasis. None required liver transplantation or developed hepatocellular or cholangiocellular malignancy. None manifested extrahepatic disease not attributable to effects of cholestasis. The variant c.2180‐5T>G resulted in exon 15 skipping with in‐frame deletion of 32 amino acid residues in TJP2. The three missense variants decreased but did not abolish TJP2 expression. Patients with truncating or canonical splice‐site variants had clinically more severe disease. TJP2 disease in children includes a full clinical spectrum of severity, with mild or intermittent forms as well as the severe and minimal forms hitherto described. Biallelic TJP2 variants must be considered in children with clinically intermittent or resolved intrahepatic cholestasis.